- Home
- Solutions
- By Diseases
- Ocular Neoplastic Diseases
- Choroidal Nevus
Choroidal nevus is a benign melanocytic lesion that occurs frequently and is considered non-threatening. Here at Protheragen, we focus on developing novel therapeutics and diagnostics for choroidal nevus. Our services encompass a full portfolio of solutions designed to fit the particular requirements of our customers.
Choroidal nevus is a type of nevus found in the eye that is usually asymptomatic and benign. Similar to a mole, it usually doesn't pose any health issues. It derives its mass from the multiplication of melanocytes found in the choroid. It is estimated that 5% to 7% of the general population suffers from this condition. Even though motability is preserved, in some cases, the choroidal nevus can worsen into choroidal melanoma or even choroidal neovascularization, which is sight-threatening.
Anti-VEGF Therapy: To execute a blockade on the endothelial growth factor (VEGF) for the therapeutics of neovascular CNV or PCV, an intravitreal injection must be administered.
Emerging Therapies: There are new developments in genetic analyses and in therapies which enable therapeutics on a more individualized basis. For instance, certain therapies that focus on genetic mutations found within the choroidal nevus cells are currently being studied.
Protheragen has developed a comprehensive package of services focused on the study of choroidal nevus, which comprises diagnostics and therapeutics development. We provide:
To facilitate the implementation of our diagnostic and therapeutic development, Protheragen has put into place extensive preclinical research capabilities. Our researchers, skilled and well-versed, together with our modern facilities, are committed to assessing the effectiveness and safety of the choroidal nevus solutions in appropriate in vitro and in vivo study models. If you are interested in our services, please feel free to contact us.
References